Pharmaceutical containing 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol and providing delayed release of the active ingredient
CA 2739611 C · Owner: Gruenenthal Gmbh · Inventors: Bartholomaeus, Johannes; Ziegler, Iris
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The invention relates to a pharmaceutical formulation which is characterised by delayed release of the active ingredient. Said formulation contains 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol or one of its pharmaceutically acceptable salts in a matrix with delayed release of the active ingredient. Said matrix contains between 1 and 80 wt.% of at least one hydrophilic or hydrophobic polymer as a pharmaceutically acceptable matrix forming agent and exhibits in vitro, the following dissolution speed: between 3 and 35 wt.% (in relation to 100 wt.% of active ingredient) of 3-(3-dimethylamino-1-ethyl-2-methyl-propyl)phenol is released after half an hour between 5 and 50 wt.% of …
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed October 22, 2002 and granted December 10, 2013. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended October 22, 2022.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by October 22, 2024.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.